Original Article
Copyright
©2011 Baishideng Publishing Group Co. , Limited. All rights reserved.
World J Gastroenterol. Feb 14, 2011; 17(6): 708-716
Published online Feb 14, 2011. doi: 10.3748/wjg.v17.i6.708
Table 1 Demographics and characteristics of patients enrolled in this study
Characteristics Total CH LC HCC P -value CH vs LC CH vs HCC LC vs HCC n (%)179 (100.0) 64 (35.8) 65 (36.3) 50 (27.9) - - - Gender (male/female) (% male) 129/50 (72.1) 38/26 (59.4) 47/18 (72.3) 44/6 (88.0) 0.121 < 0.001 0.040 Age (yr, mean ± SD) 45.8 ± 12.3 39.7 ± 13.3 49.9 ± 10.8 48.4 ± 9.5 < 0.001 < 0.001 0.495 AFP [ng/mL, median (min-max)] 13.2 (0.1-3 295 000.0) 3.2 (0.1-5039.0) 11.8 (1.0-444 718.0) 704.8 (1.2-3 295 000.0) < 0.001 < 0.001 < 0.001 AST [IU/L, median (min-max)] 66.0 (7.0-3618.0) 39.5 (7.0-481.0) 66.0 (15.0-297.0) 138.0 (9.0-3618.0) < 0.001 < 0.001 < 0.001 ALT [IU/L, median (min-max)] 50.0 (1.0-860.0) 47 (6-748) 46 (9-216) 64 (1-860) 0.480 0.481 0.123 AST/ALT 1.28 (0.1-120.6) 0.9 (0.1-2.9) 1.4 (0.2-6.0) 2.1 (0.1-120.6) < 0.001 < 0.001 < 0.001 Serum HBV DNA (log10 IU/mL, mean ± SD) 5.6 ± 2.0 6.1 ± 2.1 5.8 ± 1.4 4.6 ± 2.2 0.334 < 0.001 0.003 All HBeAg(+), (%) 71 (39.7) 36 (56.3) 19 (29.2) 16 (32.0) 0.002 0.010 0.749 All HBeAg(-), (%) 108 (60.3) 28 (43.8) 46 (70.8) 34 (68.0) HBeAg(+); HBeAb(-), (%) 71 (39.7) 36 (56.3) 19 (29.2) 16 (32.0) 0.002 0.010 0.749 HBeAg(-); HBeAb(+), (%) 86 (48.0) 22 (34.4) 40 (61.5) 24 (48.0) 0.002 0.141 0.039 HBeAg(-); HBeAb(-), (%) 22 (12.3) 6 (9.4) 6 (9.2) 10 (20.0) 0.978 0.105 0.098 Genotype B, n (%) 132 (73.7) 47 (73.4) 48 (73.8) 37 (74.0) 0.958 0.946 0.985 C, n (%) 47 (26.3) 17 (26.6) 17 (26.2) 13 (26.0)
Table 2 Comparison of hepatitis B e antigen (+) and hepatitis B e antigen (-) patients
Characteristics Total HBeAg(+) HBeAg(-) P -value n (%)179 (100.0) 71 (39.7) 108 (60.3) - Gender (male/female) (% male) 129/50 (72.1) 47/24 (66.2) 82/26 (75.9) 0.106 Age (yr, mean ± SD) 45.8 ± 12.3 40.7 ± 11.5 49.2 ± 11.7 < 0.001 AFP [ng/mL, median (min-max)] 13.2 (0.1-3 295 000.0) 10.9 (0.2-230472.0) 19.9 (0.1-3 295 000.0) 0.008 AST [IU/L, median (min-max)] 66.0 (7.0-3618.0) 55.0 (12.0-635.0) 71.0 (7.0-3618.0) 0.028 ALT [IU/L, median (min-max)] 50.0 (1.0-860.0) 47.0 (1.0-748.0) 52.0 (6.0-860.0) 0.535 AST/ALT 1.3 (0.1-120.6) 1.1 (0.1-30.8) 1.4 (1.4-120.6) 0.022 Serum HBV DNA (log10 IU/mL, mean ± SD) 5.6 ± 2.0 6.5 ± 1.8 5.0 ± 1.9 < 0.001 < 20 000 IU/mL, n (%) 40 (22.3) 6 (8.5) 34 (31.5) < 0.001 ≥ 20 000 IU/mL, n (%) 139 (77.7) 65 (91.5) 74 (68.5) Clinical status CH, n (%) 64 (35.8) 36 (50.7) 28 (25.9) 0.003 LC, n (%) 65 (36.3) 19 (26.8) 46 (42.6) HCC, n (%) 50 (27.9) 16 (22.5) 34 (31.5) Genotype B, n (%) 132 (73.7) 50 (70.4) 82 (75.9) 0.259 C, n (%) 47 (26.3) 21 (29.6) 26 (24.1)
Table 3 Comparison of patients with hepatitis B e antigen (+), before and after hepatitis B e antigen seroconversion
Characteristics Group 1 Group 2 Group 3 P -value HBeAg(+), HBeAb(-) HBeAg(-), HBeAb(+) HBeAg(-), HBeAb(-) 1 vs 2 1 vs 3 2 vs 3 n (%)71 (39.7) 86 (48.0) 22 (12.3) - - - Gender (male/female) (% male) 47/24 (66.2) 71/15 (82.6) 11/11 (50.0) 0.018 0.171 0.001 Age (yr, mean ± SD) 40.7 ± 11.5 49.8 ± 11.9 46.9 ± 10.6 < 0.001 0.028 0.296 AFP [ng/mL, median (min-max)] 10.9 (0.2-230 472.0) 17.1 (0.1-3 295 000.0) 40.8 (0.4-514 412.0) 0.016 0.048 0.731 AST [IU/L, median (min-max)] 55.0 (12.0-635.0) 68.0 (7.0-3618.0) 76.5 (9.0-580.0) 0.017 0.536 0.448 ALT [IU/L, median (min-max)] 47.0 (1.0-748.0) 60.0 (9.0-860.0) 43.0 (6.0-154.0) 0.200 0.173 0.023 AST/ALT 1.1 (0.1-30.8) 1.3 (0.1-120.6) 1.7 (0.5-6.0) 0.091 0.007 0.052 Serum HBV DNA (log10 IU/mL, mean ± SD) 6.5 ± 1.8 5.1 ± 1.8 4.5 ± 2.4 < 0.001 < 0.001 0.146 < 20 000 IU/mL, n (%) 6 (8.5) 25 (29.1) 9 (40.9) 0.001 < 0.001 0.286 ≥ 20 000 IU/mL, n (%) 65 (91.5) 61 (70.9) 13 (59.1) Clinical status CH, n (%) 36 (50.7) 22 (25.6) 6 (27.3) 0.001 0.054 0.871 LC, n (%) 19 (26.8) 40 (46.5) 6 (27.3) 0.011 0.963 0.104 HCC, n (%) 16 (22.5) 24 (27.9) 10 (45.4) 0.442 0.036 0.114 Genotype B, n (%) 50 (70.4) 66 (76.7) 16 (72.7) 0.369 0.835 0.694 C, n (%) 21 (29.6) 20 (23.3) 6 (27.3)
Table 4 Precore and core promoter mutations in patients with hepatitis B e antigen (+), before and after hepatitis B e antigen seroconversion n (%)
All Group 1 Group 2 Group 3 Group 2+3 P -value HBeAg(+), HBeAb(-) HBeAg(-), HBeAb(+) HBeAg(-), HBeAb(-) HBeAg(-) 1 vs 2 1 vs 3 2 vs 3 1 vs (2+3) T1762/A17641 Absent 90 (50.3) 42 (59.2) 38 (44.2) 10 (45.5) 48 (44.4) 0.062 0.258 0.915 0.054 Present 89 (49.7) 29 (40.8) 48 (55.8) 12 (54.5) 60 (55.6) A18962 Absent 65 (61.3) 48 (100.0)3 15 (34.9) 2 (13.3) 17 (29.3) < 0.001 < 0.001 0.114 < 0.001 Present 41 (38.7) 0 (0.0) 28 (65.1) 13 (87.7) 41 (70.7) A18992 Absent 81 (76.4) 43 (89.6) 27 (62.8) 11 (73.3) 38 (65.5) 0.003 0.034 0.116 0.004 Present 25 (23.6) 5 (10.4) 16 (37.2) 4 (26.7) 20 (34.5) T1762/A1764 and A18962 Absent 88 (83.0) 48 (100.0) 31 (72.1) 9 (60.0) 40 (68.9) < 0.001 < 0.001 0.383 < 0.001 Present 18 (17.0) 0 (0.0) 12 (27.9) 6 (40.0) 18 (31.0) T1762/A1764 or A18962 Absent 33 (31.1) 31 (64.6) 2 (4.7) 0 (0.0) 2 (1.9)4 < 0.001 < 0.001 0.395 < 0.001 Present 73 (68.9) 17 (35.4) 41 (95.3) 15 (100.0) 56 (98.1)
Table 5 Precore and core promoter mutations in samples with hepatitis B e antigen (-) and hepatitis B e antibody (-)
No. Sample ID T1762/A1764 A1896 A1899 Serum HBV DNA (log10 IU/mL) 1 07.10.068 Yes No No 4.59 2 08.70.091 Yes No No 4.87 3 08.100.038 Yes Yes No 6.43 4 07.10.121 Yes Yes No 7.52 5 08.10.002 Yes Yes No 7.18 6 09.41.591 Yes Yes Yes 6.53 7 09.40.037 Yes Yes Yes 5.62 8 10.80.004 Yes Yes No 2.78 9 06.10.062 No Yes No 3.32 10 08.10.086 No Yes No 4.94 11 09.40.033 No Yes No 7.28 12 09.80.040 No Yes No 4.05 13 09.41.806 No Yes Yes 7.42 14 07.10.070 No Yes Yes 4.72 15 09.80.037 No Yes Yes 6.78 16 08.10.016 Yes NA NA 5.21 17 08.10.020 Yes NA NA -0.37 18 08.10.039 Yes NA NA 3.10 19 P.X00.34 Yes NA NA -0.54 20 07.10.117 No NA NA 1.73 21 07.10.026 No NA NA 1.27 22 07.10.173 No NA NA 3.48
Table 6 Precore and core promoter mutations related to serum hepatitis B virus DNA and alanine aminotransferase in hepatitis B e antigen (+) patients
Serum HBV DNA (log10 IU/mL) (mean ± SD) (n ) P -value ALT (IU/L) [median (min-max)] (n ) P -value Absent Present Absent Present T1762/A17641 7.14 ± 1.46 (42) 5.60 ± 1.99 (29) < 0.001 43.5 (13.0-748.0) (42) 48.5 (1.0-215.0) (29) 0.806 A18962 6.98 ± 1.27 (48) - - 47.0 (1.0-748.0) (48) - - A18992 7.01 ± 1.25 (43) 6.68 ± 1.53 (5) 0.609 45.5 (1.0-748.0) (43) 55.0 (36.0-92.0) (5) 0.627 T1762/A1764 and A18962 6.98 ± 1.27 (48) - - 47.0 (1.0-748.0) (48) - - T1762/A1764 or A18962 7.33 ± 1.23 (31) 6.33 ± 1.08 (17) 0.011 50.0 (15.0-748.0) (31) 41.5 (1.0-117.0) (17) 0.459
Table 7 Precore and core promoter mutations related to serum hepatitis B virus DNA and alanine aminotransferase in hepatitis B e antigen (-) patients
Serum HBV DNA (log10 IU/mL) (mean ± SD) (n ) P -value ALT (IU/L) [median (min-max)] (n ) P -value Absent Present Absent Present T1762/A17641 4.64 ± 2.00 (48) 5.23 ± 1.79 (60) 0.095 57.0 (6.0-302) (48) 51.5 (6.0-860.0) (60) 0.885 A18962 5.44 ± 1.66 (17) 5.91 ± 1.35 (41) 0.231 46.0 (15.0-860.0) (17) 63.5 (14.0-302.0) (41) 0.321 A18992 5.80 ± 1.29 (38) 5.72 ± 1.76 (20) 0.382 52.0 (14.0-860.0) (38) 58.5 (17.0-302.0) (20) 0.693 T1762/A1764 and A18962 5.59 ± 1.51 (40) 6.17 ± 1.27 (18) 0.138 65.0 (14.0-860.0) (40) 51.0 (17.0-174.0) (18) 0.543 T1762/A1764 or A18962 2.77 ± 4.31 (2) 5.88 ± 1.23 (56) < 0.001 59.5 (23.0-96.0) (2) 52.0 (42.0-860.0) (56) 0.847
Citation: Utama A, Siburian MD, Purwantomo S, Intan MDB, Kurniasih TS, Gani RA, Achwan WA, Arnelis, Lelosutan SA, Lukito B, Harmono T, Zubir N, Julius, Soemohardjo S, Lesmana LA, Sulaiman A, Tai S. Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients. World J Gastroenterol 2011; 17(6): 708-716
URL: https://www.wjgnet.com/1007-9327/full/v17/i6/708.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i6.708